Charles River Laboratories (CRL) Tops Q3 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $338.54 --0%
EPS Growth %: +22.2%
Financial Fact:
Net sales related to products: 132.87M
Today's EPS Names:
INM, TRI, CRVL, More
EPS Growth %: +22.2%
Financial Fact:
Net sales related to products: 132.87M
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $1.53, $0.15 better than the analyst estimate of $1.38. Revenue for the quarter came in at $585.3 million versus the consensus estimate of $567.79 million.
GUIDANCE:
Charles River Laboratories sees FY2018 EPS of $5.87-$5.97, versus the consensus of $5.92.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sotera Health Co. (SHC) Tops Q3 EPS by 2c; Offers Guidance
- The Marzetti Company (MZTI) Misses Q3 EPS by 23c
- Lindblad Expeditions Holdings (LIND) Tops Q3 EPS by 1c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
